The ROE as of December 2024 (TTM) for Capricor Therapeutics, Inc. (CAPR) is -112.95%

According to Capricor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -112.95%. This represents a change of 164.95% compared to the average of -42.63% of the last 4 quarters.

Capricor Therapeutics, Inc. (CAPR) Historical ROE (quarterly & annually)

How has CAPR ROE performed in the past?

The mean historical ROE of Capricor Therapeutics, Inc. over the last ten years is 94.56%. The current -112.95% ROE has changed -219.45% with respect to the historical average. Over the past ten years (40 quarters), CAPR's ROE was at its highest in in the March 2023 quarter at 6.58%. The ROE was at its lowest in in the September 2016 quarter at -10855.49%.

Capricor Therapeutics, Inc. (CAPR) ROE by Quarter and Year

Discovering the peaks and valleys of Capricor Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Capricor Therapeutics, Inc. (CAPR) Average ROE

How has CAPR ROE performed in the past?

The current ROE of Capricor Therapeutics, Inc. (CAPR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Capricor Therapeutics, Inc. (CAPR) ROE vs. Peers

How is CAPR’s ROE compared to its peers?

Capricor Therapeutics, Inc.’s ROE is less than Bio-Path Holdings, Inc. (2.62%), greater than Catalyst Biosciences, Inc. (-63.14%), greater than Diffusion Pharmaceuticals Inc. (-44.12%), greater than NextCure, Inc. (-62.50%), greater than Pulmatrix, Inc. (-63.07%), less than Akari Therapeutics, Plc (550.78%), greater than Soleno Therapeutics, Inc. (-61.99%), greater than Unicycive Therapeutics, Inc. (-374.14%), greater than Cidara Therapeutics, Inc. (-219.21%), greater than Phio Pharmaceuticals Corp. (-134.57%), less than Onconova Therapeutics, Inc. (619.75%), greater than Moleculin Biotech, Inc. (-165.56%), greater than IDEAYA Biosciences, Inc. (-19.42%), greater than AnaptysBio, Inc. (-287.94%), greater than MeiraGTx Holdings plc (-80.95%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Homology Medicines, Inc. (-100.91%),

Build a custom stock screener for Capricor Therapeutics, Inc. (CAPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Capricor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Capricor Therapeutics, Inc. (CAPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Capricor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.